Endothelial Nitric Oxide Synthase Inhibits G12/13and Rho-Kinase Activated by the Angiotensin II Type-1 Receptor

Authors:
  • KKKeita Kimura
    Keita Kimura
  • HSHeigoro Shirai
    Heigoro Shirai
  • KEKunie Eguchi
    Kunie Eguchi
  • SHSadaharu Higuchi
    Sadaharu Higuchi
  • AHAkinari Hinoki
    Akinari Hinoki
  • EBEugen Brailoiu
    Eugen Brailoiu
  • DDDanny N. Dhanasekaran
    Danny N. Dhanasekaran
  • LSLaura N. Stemmle
    Laura N. Stemmle
  • TFTimothy A. Fields
    Timothy A. Fields
  • GFGerald D. Frank
    Gerald D. Frank

Abstract
Background—Although, endothelial nitric oxide (NO) synthase (eNOS) is believed to antagonize vascular remodeling induced by the angiotensin II (AngII) type-1 receptor, the exact signaling mechanism remains unclear.Methods and Results—By expressing eNOS to vascular smooth muscle cells (VSMCs) via adenovirus, we investigated a signal transduction mechanism of the eNOS gene transfer in preventing vascular remodeling induced by AngII. We found marked inhibition of AngII-induced Rho/Rho-kinase activation and subsequent VSMC migration by eNOS gene transfer whereas Gq-dependent transactivation of the epidermal growth factor receptor by AngII remains intact. This could be explained by the specific inhibition of G12/13activation by eNOS-mediated G12/13phosphorylation.Conclusion—The eNOS/NO cascade specifically targets the Rho/Rho-kinase system via inhibition of G12/13to prevent vascular migration induced by AngII, representing a novel signal cross-talk in cardiovascular protection by NO.

This publication has 57 references indexed in Scilit: